Keryx Biopharmaceuticals to Present at the 15th Annual BIO CEO & Investor
Conference Presentation Scheduled for Monday, February 11th at 2:30 PM ET
NEW YORK, Feb. 8, 2013
NEW YORK, Feb. 8, 2013 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq:
KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer,
will be presenting at the 15th Annual BIO CEO & Investor Conference, being
held February 11-12, 2013, in New York City. Mr. Bentsur's presentation is
scheduled to take place on Monday, February 11^th, at 2:30 PM ET.
A live audio webcast of Mr. Bentsur's presentation will be accessible from the
Investor Information page of the Company's Website at
http://investors.keryx.com. An archived version of the webcast will be
available following the conclusion of the live presentation.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals is focused on the acquisition, development and
commercialization of medically important pharmaceutical products for the
treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an
oral, ferric iron-based compound that has the capacity to bind to phosphate
and form non-absorbable complexes. Zerenex has completed a U.S.-based Phase 3
clinical program for the treatment of hyperphosphatemia (elevated phosphate
levels) in patients with end-stage renal disease, conducted pursuant to a
Special Protocol Assessment (SPA) agreement with the FDA, and Keryx expects to
submit an NDA with the FDA and a MAA with the EMA in the second quarter of
2013. Zerenex is also in Phase 2 development in the U.S. for the management
of phosphorus and iron deficiency in anemic patients with Stage 3 to 5
non-dialysis dependent chronic kidney disease. In addition, Keryx's Japanese
partner, Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. has filed its
New Drug Application for marketing approval of ferric citrate in Japan for the
treatment of hyperphosphatemia in patients with chronic kidney disease. Keryx
is headquartered in New York City.
Director - Investor Relations
Keryx Biopharmaceuticals, Inc.
SOURCE Keryx Biopharmaceuticals, Inc.
Press spacebar to pause and continue. Press esc to stop.